Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox®

Philippe Berben, Jef Stappaerts, Matthias J.A. Vink, Elena Domínguez-Vega, Govert W. Somsen, Joachim Brouwers, Patrick Augustijns*

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

108 Downloads (Pure)

Abstract

In a previously performed small-scale clinical study, healthy volunteers were asked to ingest an oral solution of itraconazole (Sporanox®) containing 40% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) (i) with or (ii) without a standardized volume of water (240 mL) after which gastrointestinal and blood samples were collected. Although omitting water during the administration of Sporanox® resulted in noticeably higher duodenal concentrations of itraconazole, systemic exposure was almost unaffected. It is assumed that this discrepancy can be explained by differences in the extent of entrapment of itraconazole in the duodenum caused by differential complexation depending on the concentration of cyclodextrins. To further substantiate this hypothesis, the quantification of HP-β-CD concentrations in the aspirated intestinal fluids was performed by LC-MS/MS. When comparing the intestinal concentrations of itraconazole and HP-β-CD for one single healthy volunteer (HV02) in both test conditions, an excellent correlation was observed (Spearman's rank coefficient of 0.96). Moreover, the data suggest that, similar to aqueous buffer media, also in human intestinal fluids a non-linear relationship exists between itraconazole solubility and HP-β-CD concentration (Ap-type profile; Spearman's rank coefficient of 0.78), indicating that higher order complexes are formed at higher concentrations of HP-β-CD. This difference in extent of entrapment in the inclusion complexes helps to understand the observed impact of water intake on precipitation and permeation behavior of itraconazole in man. Without water intake, higher HP-β-CD concentrations resulted in less precipitation and increased duodenal concentrations of itraconazole. On the other hand, the stronger interaction at higher HP-β-CD concentrations reduced the free fraction of the drug explaining that increased intraluminal concentrations of itraconazole were not translated into an enhanced uptake. In conclusion, quantifying the concentrations of the solubilizing agent HP-β-CD in human intestinal fluids appeared to be of crucial importance to interpret the intraluminal behavior of an orally administered cyclodextrin-based solution.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume132
Early online date27 Jun 2018
DOIs
Publication statusPublished - Nov 2018

Funding

This work has received support from (1) the Innovative Medicines Initiative Joint Undertaking ( http://www.imi.europe.eu ) under Grant Agreement No. 115369 , resources of which are composed of financial contribution from the European Union’s Seventh Framework Program and EFPIA companies’ in kind contribution and from (2) the Institute for the Promotion of Innovation though Science and Technology in Flanders (IWT) (Grant No. 135040 ).

FundersFunder number
Institute for the Promotion of Innovation though Science and Technology in Flanders
Seventh Framework Programme
European Federation of Pharmaceutical Industries and Associations
Agentschap voor Innovatie door Wetenschap en Technologie135040
Seventh Framework Programme
Innovative Medicines Initiative115369

    Keywords

    • Clinical trial
    • Human intestinal fluids (HIF)
    • Hydroxypropyl-β-cyclodextrin (HP-β-CD)
    • Itraconazole
    • LC-MS/MS

    Fingerprint

    Dive into the research topics of 'Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox®'. Together they form a unique fingerprint.

    Cite this